RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:The 2nd PPInfinity ... Are you trying to tell us that Roger invested 20y to innovate not to reach the end game??? And this, right after having added more, from his own pocket (May 14 warrants conversion) and taking part in the Sept. 22 pp???
Wow! You would be that type of entrepreneure???
Don't you think he wouldn't take pride in bringing PDT/PDC to bedside and mainstream??? Imagine the pride one would achieve, over big pharmas!
As for your "Market factor" statement, innovators and trailblazers always have the burden to demonstrate that the superficial naysayers are wrong. They have room for no error. It's always been ike that and will ever be. It was true for many inventors, from the inventor of laparoscopy to Elon Musk (TESLA and then SPACEX), etc .... Rutherrin was supposed to be more damaging to patients than chemo, as per the big pharmas beliefs. That's rather the contrary now, and it comes with even higher efficacy! Roger, prof. Lilge, Prof. McFarland have come to great efforts to show this and so far, Ph.1 and 2 have proven them right.
So the market will listen, if we get convincing data, superior data (over SOC), Breakthrough designation, Accelerated Approval.
So there's no plot theories here. It's all about market shares for big pharmas. One of them will move faster than its competitors if they feel our treatment bring them higher market shares.
______________________
Infinity - (10/9/2022 10:05:30 AM)
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:The 2nd PP
Steven, Yes, I admit, I could be wrong. I still have a substantial stake in TLT since I believe in the treatment and the success so far. NOW, I am beginning to have my own doubts about the Management and their actions in reaching the END GAME, that is to offer a better alternative to existing treatments for Cancer... Steven, you are welcome to bash me all day long, there is one factor called the "Market" that will determine the selling price for this stock.